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Background: Vascular risk factors, such as diabetes mellitus (DM), are associated with poorer outcomes 
following many neurodegenerative diseases, including hemorrhagic stroke and Alzheimer’s disease (AD). 
Combined AD and DM co-morbidities are associated with an increased risk of hemorrhagic stroke and 
increased Medicare costs. Therefore, we hypothesized that patients with DM in combination with AD, 
termed DM/AD, would have increased hemorrhagic stroke severity.
Methods: Kentucky Appalachian Stroke Registry (KApSR) is a database of demographic and clinical data 
from patients that live in Appalachia, a distinct region with increased health disparities and stroke severity. 
Inpatients with a primary indication of hemorrhagic stroke were selected from KApSR for retrospective 
analysis and were separated into four groups: DM only, AD only, neither, or both.
Results: Hemorrhagic stroke patients (2,071 total) presented with either intracerebral hemorrhage (ICH), 
n=1,448, or subarachnoid hemorrhage (SAH), n=623. When examining all four groups, subjects with AD 
were significantly older (AD+, 80.9±6.6 yrs) (DM+/AD+, 77.4±10.0 yrs) than non AD subjects (DM-/AD-, 
61.3±16.5 yrs) and (DM+, 66.0±12.5 yrs). A higher percentage of females were among the AD+ group 
and a higher percentage of males among the DM+/AD+ group. Interestingly, after adjusting for multiple 
comparison, DM+/AD+ subjects were ten times as likely to suffer a moderate to severe stroke based on a 
National Institute of Health Stroke (NIHSS) upon admission [odds ratio (95% CI)] compared to DM-/
AD- [0.1 (0.02–0.55)], DM+ [0.11 (0.02–0.59)], and AD+ [0.09(0.01–0.63)]. The odds of DM+/AD+ subjects 
having an unfavorable discharge destination (death, hospice, long-term care) was significant (P<0.05) from 
DM-/AD- [0.26 (0.07–0.96)] when adjusting for sex, age, and comorbidities.
Conclusions: In our retrospective analysis utilizing KApSR, regardless of adjusting for age, sex, and 
comorbidities, DM+/AD+ patients were significantly more likely to have had a moderate or severe stroke 
leading to an unfavorable outcome following hemorrhagic stroke.
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Introduction
Kentucky and West Virginia lie within a portion of rural 
Appalachia, a population with an increased burden of 
negative health disparities (1-3). According to the United 
Heath Foundation, as of 2019, Kentucky and West Virginia 
ranked 43rd and 45th out of 50, respectively, for overall 
health in the US. Contributing to this overall negative heath 
disparity are their rankings of 44th and 46th for stroke and 
44th and 50th for diabetes, respectively. Using Medicare 
costs as a measure of overall health (i.e., high Medicare cost 
indicates poor health), diabetes mellitus (DM; i.e., type 2 
diabetes), has been shown to increase cost by a factor of 
2.3 (4). DM is associated with an increased risk of 
Alzheimer’s disease (AD) (5-7) and poorer outcomes 
following stroke (8). AD is also an additive comorbidity 
that doubles Medicare cost when associated with stroke 
and diabetes (9) and has an increased risk of hemorrhagic 
stroke (10). Stroke, AD, and DM are among the top 7 
leading causes of death, not only in Kentucky and West 
Virginia (11), but globally (12). Many retrospective studies 
have examined how a single comorbidity influences a 
neurological disease, such as hemorrhagic stroke, but few 
have looked at the effect of dual comorbidities or specifically 
how AD influences hemorrhagic stroke outcomes.
The Kentucky Appalachian Stroke Registry (KApSR) is 
a database of demographic and clinical data from patients 
in the rural Kentucky and West Virgina regions with 
stroke (13). In this study, we used KApSR to retrospectively 
analyze the contributions of diabetes and AD to outcomes 
following hemorrhagic stroke such as length of stay, 
discharge destination, change in National Institute of 
Health Stroke (NIHSS), and 30-day readmission rates. Our 
central aim was to examine the relationship between the 
combination of diabetes and AD and hemorrhagic stroke 
severity.
We present the following article in accordance with the 




The study was conducted in accordance with the 
Declaration of Helsinki (as revised in 2013). The study 
was approved by Kentucky Appalachian Stroke Registry 
(KApSR) (de-identified data provided under IRB# 13-
08058) and individual consent for this retrospective analysis 
was waived.
Study sample
Kentucky Appalachian Stroke Registry (KApSR) is a 
database of demographic and clinical data from patients 
that live in Appalachia Kentucky (13), a distinct region with 
increased health disparities and stroke severity. A cross-
sectional analysis of inpatients with cardiovascular disease 
(CVD) containing a principle diagnosis of hemorrhagic 
stroke were evaluated for DM and/or AD in the KApSR 
database from 2010–2018. Hemorrhagic stroke patients 
were identified in KApSR as presenting with intracerebral 
hemorrhage (ICH) or subarachnoid hemorrhage (SAH), 
methods previously described (13). Briefly, demographics, 
comorbidities (defined by International Classification of 
Disease (ICD) codes), glycated hemoglobin A1 (hbA1c) 
values, previous diagnosis of AD, and outcome measures 
were collected from electronic health records (EHR) for 
inpatients, >18 years old, with an ICH or SAH, ICD9 codes: 
431 and 430; ICD10 codes of 161 and 160, respectively. The 
accuracy of using EHR in KApSR was previously validated 
and reported by Kitzman et al. (13). We separated patients 
into four comorbidity categories: no previous diagnosis of 
DM or AD (DM-/AD-), DM only (DM+), AD only (AD+), 
or combined DM and AD (DM+/AD+).
Outcomes
Admission and discharge NIHSS were collected, along 
with length of stay, and discharge destination (favorable or 
unfavorable). Favorable discharge destinations include: alive/
routine, transfer to other institution, hospital swing bed, 
or home health services, rehabilitation facility/unit, against 
medical advice, police case, or billin. Unfavorable discharge 
destinations include: death (≤48 or >48 hrs), hospice, skilled 
nursing facility, or long-term care hospital. Change in 
NIHSS from admission to discharge was measured as an 
indicator of short-term inpatient outcome (14).
Statistical analysis
Demographic characteristics are presented without 
adjustment for covariates as mean ± standard deviation 
or sample number (percentages). A1Cs were categorized 
as normal (<5.7%) or as abnormal (≥5.7%) (15,16) that 
included diabetics (A1C ≥6.5%) and prediabetics (5.7≤ 
A1C <6.5) (17). Between-group differences in demographic 
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characteristics were investigated using a series of one-
way ANOVAs for continuous variables and Chi-square or 
Fisher’s exact tests for categorical variables. Differences 
in non-normal continuous variables were assessed using a 
Kruskal-Wallis test. Significant between group differences 
were used as control variables in model 3 of the main 
outcome analysis (described below). To investigate between 
group differences in the main outcome variables, three 
models were employed. Model 1 was unadjusted, model 
2 was adjusted for age and sex, and model 3 was adjusted 
for age, sex, type of hemorrhage, race, and all significant 
comorbidities (other than DM and AD). The DM/AD was 
the reference group for all analyses. Depending on the 
distribution of the outcome, these models were analyzed 
using linear regression, logistic regression, or ordinal 
logistic regression. Due to its non-normal distribution and 
inability to achieve normality under any data transformation, 
NIHSS was recoded into an ordinal variable defined as: 0–5= 
mild, 6–13= moderate, and >13= severe stroke (18-20). The 
change (Admission-Discharge) in NIHSS was transformed 
into an ordinal variable based on whether the patient was: 
declining, staying the same, or improving. This change 
was based on the continuous NIHSS value. Discharge 
destination, a binary variable, was classified as favorable or 
unfavorable using the rules outlined above. Length of stay 
positively skewed and was log transformed to approximate 
normality. For all models, odds ratios and 95% confidence 
intervals (CI) were calculated for all outcome measures. 
For each outcome, Dunnett’s procedure was used to correct 
for multiple comparisons, since each category was being 
compared against the DM/AD condition (21). Graphical 
and statistical analysis was performed using Graphpad 
Prism and SAS version 9.4 (SAS Institute Inc.).
Missing data and statistical assumption
NIHSS, the main outcome, was missing for 40.2% (n=833) 
of the sample. Our hospital institution transitioned from 
the Primary Stroke Center to a Comprehensive Stroke 
Center in 2013, and our standards and mechanisms for 
documentation in the EMR changed. These evolutions 
could account for missing data points in our study, which, 
unfortunately, could not be recovered. A missing data 
analysis was performed using demographic and comorbidity 
variables as predictors of missingness in a multivariable 
logistic regression. Table S1 (see supplemental materials) 
contains the results of this analysis. The following 
characteristics and comorbidities were associated with 
lower odds of having missing NIHSS: older age, current 
hypertension, tobacco use, dyslipidemia and carotid 
stenosis. Females and those with SAH stroke type had 
higher levels of missing data. There were no significant 
differences between AD or DM conditions. These variables 
were included in the models where NIHSS were the 
outcome of interest. No covariates contained missing data.
As a result of missing NIHSS data and a small sample 
for the main comparison condition (DM+/AD+), a there is 
a concern for the violation of statistical assumptions due to 
the small expected cell sizes for the contingency tables of 
Model 1 (described above). To address this concern, Fisher’s 
exact tests, a nonparametric version of a chi-square test of 
independence, was performed on NIHSS outcomes for all 
pairwise comparisons where DM+/AD+ was the reference 
group. The substantive results of these tests aligned with 
the parametric versions reported in the results. Despite 
certain statistical assumptions of our model not being met, 
the agreement between these two sets of analyses lends 
credence to our interpretations.
Results
Demographic characteristics
A total of 2,071 patients with hemorrhagic stroke were 
included: 1,459 (70.4%) were without DM and AD (DM-/
AD-), 567 (27.4%) had DM alone (DM+), 29 (1.4%) had 
AD alone (AD+), and 16 had both DM and AD (DM+/
AD+). Table 1 presents descriptive statistics for the 
demographic and comorbidity variables with between group 
comparisons. There were significant (P<0.0001) differences 
in the age of the groups (Figure 1A): 61.3±16.5 yrs (DM-/
AD-) to 66.01±12.5 yrs (DM+), 80.9±6.6 yrs (AD+), and 
77.4±10.0 yrs (DM+/AD+). Patients with an AD diagnosis 
(AD+ or DM+/AD+) were significantly (P<0.0001, P<0.05, 
respectively) older than DM alone. Sex was significantly 
(P<0.05) different among the groups, with ~50% female 
for DM-/AD- and DM+ to ~76% female in AD+ and 
~31% female in DM+/ AD+ (Figure 1B). A significantly 
higher percentage of DM+ (P<0.0001) and AD+ (P<0.01), 
compared to the DM-/AD- (Figure 1C), had a prior 
stroke. DM+/AD+ followed this trend but did not reach 
significance (P=0.08). No statistical difference among race 
in the four groups was observed (Table 1). Across the four 
groups, ICH was more common than SAH (Figure 1D), 
with DM+ and AD+ having significantly more ICH than 
SAH compared to DM-/AD-.
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Table 1 Demographics of hemorrhagic stroke patients in KApSR
Variable -DM/-AD DM AD DM/AD Test statistic P value
Total N 1,459 (70.4%) 567 (27.4%) 29 (1.4%) 16 (0.8%)
Age, yrs (mean ± SD) 61.3±16.5 66.0±12.5 80.9±6.6 77.4±10.0 31.1 <0.0001
Sex, female, N (%) 745 (51.1%) 290 (51.1%) 22 (75.9%) 5 (31.3%) 9.615 0.0221
Stroke type, ICH, n (%) 974 (66.8%) 436 (76.9%) 25 (86.2%) 13 (81.3%) 24.69 <0.0001
Race, n (%) 0.2954
White 1,317 (90.3%) 565 (99.8%) 29 (100%) 12 (75%)
Black 107 (7.3%) 0 0 4 (25%)
Asian 11 (0.8%) 0 0 0
Hispanic 3 (0.2%) 0 0 0
Other/non-Hispanic 8 (0.5%) 1 (0.2%) 0 0
Refused/unreported 13 (0.9%) 1 (0.2%) 0 0
Comorbidities, n (%)
Prior stroke/transient ischemic attack 225 (15.4%) 130 (22.9%) 10 (34.5%) 5 (31.3%) 23.25 <0.0001
Atrial fibrillation 208 (14%) 131 (23%) 9 (31.0%) 6 (38.0%) 31.42 <0.0001
Coronary artery disease 258 (17.7%) 205 (36.2%) 11 (37.9%)) 9 (56.3%) 91.32 <0.0001
Dyslipidemia 470 (32.2%) 324 (57.1%) 14 (48.3%) 10 (62.5%) 110.7 <0.0001
Hypertension 1,233 (84.6%) 544 (95.9%) 22 (75.9%) 14 (87.5%) 52.63 <0.0001
Obesity 177 (12.1%) 127 (22.4%) 2 (6.9%) 1 (6.25%) 36.52 <0.0001
Carotid stenosis 42 (2.9%) 36 (6.3%) 1 (3.4%) 0 14.06 0.0048
History of myocardial infarction 72 (4.9%) 45 (7.9%) 1 (3.4%) 2 (12.5%) 8.351 0.0301
Acute myocardial infarction 78 (5.3%) 41 (7.2%) 0 (0) 2 (12.5%) 5.729 0.1036
Tobacco 600 (41.2%) 188 (33.2%) 6 (20.7%) 6 (37.5%) 15.14 0.0014
hbAIc
n 413 369 12 11
Mean ± SD 5.6±0.7 7.5±1.9 5.4±0.4 6.6±0.6 119.2 <0.0001
≥5.7 AIC (%) 162 (39.0%) 326 (88%) 6 (50%) 10 (100) 207.8 <0.0001
Outcomes†
Admission NIHSS value, median [IQR] 7 [1–19] 7 [2–18] 9 [2–23] 19 [15–26]
Ordinal admission NIHSS, n (%)
Mild: 0–5 389 (46.6%) 160 (43.4%) 9 (39.1%) 1 (9.1%)
Moderate: 6–13 166 (19.9%) 78 (21.1%) 6 (26.1%) 1 (9.1%)
Severe: >13 280 (33.5%) 131 (35.5%) 8 (34.8%) 9 (81.8%)
Discharge NIHSS value, median [IQR] 6 [1–18] 6 [1–19] 12 [4–23] 19 [10–22]
Table 1 (continued)
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Table 1 (continued)
Variable -DM/-AD DM AD DM/AD Test statistic P value
Ordinal discharge NIHSS, n (%)
Mild: 0–5 412 (49.3%) 179 (48.5%) 7 (30.4%) 0 (0%)
Moderate: 6–13 149 (17.8%) 68 (18.4%) 5 (21.7%) 4 (36.4%)
Severe: >13 274 (32.8%) 122 (33.1%) 11 (47.8%) 7 (63.6%)
NIHSS change value, median [IQR] 0 [−1 to 1] 0 [−1 to 2] 0 [−4 to 1] 1 [0 to 7]
Ordinal NIHSS change, n (%)
Decline 228 (27.3%) 108 (29.3%) 9 (39.1%) 2 (18.2%)
Stable 332 (39.8%) 122 (33.1%) 7 (30.4%) 3 (27.3%)
Improve 275 (32.9%) 139 (37.7%) 7 (30.4%) 6 (54.6%)
Unfavorable discharge, n (%) 571 (39.1%) 240 (42.3%) 18 (62.1%) 12 (75.0%)
Length of stay (log), mean (SD) 1.63 (1.16) 1.71 (1.09) 1.28 (0.90) 1.83 (1.10)
Data are mean ± SD and number with percent of population. †, statistical analysis for outcome presented in Model 1 of Table 2. AD, 
Alzheimer’s disease; DM, diabetes mellitus; F, female; hbA1c, glycosylated hemoglobin A1c; ICH, intracerebral hemorrhage; IQR, 
interquartile range; KApSR, Kentucky Appalachian Stroke Registry; M, male; NIHSS, National Institutes of Health Stroke Scale; SD, 
standard deviation; SAH, subarachnoid hemorrhage.
Figure 1 Hemorrhagic stroke demographic among KApSR. The average (A) age as well as percentage of (B) males to females, (C) patients 
with a prior stroke, and (D) type of hemorrhagic stroke among the four subgroups (-DM/-AD, DM, AD, and DM/AD). Data are mean ± 
SEM. P values were assessed by ANOVA or Chi-squared followed by followed by a Tukey’s post-hoc test or a 2×2 Chi-squared. *, P<0.05; **, 
P<0.01; ***, P<0.001; ****, P<0.0001 indicates significance from -DM/-AD. ^, P<0.05; ^^, P<0.01; and ^^^^, P<0.0001 indicates significance 
from DM. #P<0.05 indicates significance from AD. AD, Alzheimer’s disease; ANOVA, Analysis of Variance; DM, diabetes mellitus; ICH, 
intracerebral hemorrhage; KApSR, Kentucky Appalachian Stroke Registry; TIA, transient ischemic attack; SEM, standard error of mean; 
SAH, subarachnoid hemorrhage; yrs, years.
A B
C D
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Figure 2 Comorbidities among KApSR patients with hemorrhagic stroke. The percentage of patients with (A) atrial fibrillation, (B) 
coronary artery disease, (C) dyslipidemia, (D) hypertension, (E) obesity, (F) hbA1c ≥5.6, and (G) tobacco use among the four subgroups 
(–DM/-AD, +DM, +AD, and DM/AD). Data are represented as percentage of yes/no. P values were assessed by Chi-squared, 4×2, followed 
by followed 2×2. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 indicates significance from -DM/-AD. ^P<0.05 and ^^^^P<0.0001 indicates 






When evaluating comorbidities, a significantly higher 
percentage of patients with atrial fibrillation (P<0.0001, 
Figure 2A) and coronary artery disease (P<0.0001, Figure 2B) 
were seen in DM+, AD+, and DM+/AD+ compared to 
DM-/AD-. Dyslipidemia was only significantly (P<0.0001) 
different among the subjects with DM (DM+ and DM+/
AD+, Figure 2C) compared to DM-/AD-. Hypertension 
(P<0.0001, Figure 2D) and obesity (P<0.0001, Figure 2E) 
increased in subjects with only DM, compared to DM-/AD- 
and the AD groups. Differences in carotid stenosis (P<0.01) 
and a history of, but not acute, myocardial infarction 
(P<0.05) were observed with only the DM group compared 
to the DM-/AD- group (Table 1). A significantly (P<0.0001, 
Figure 2F) higher percentage of patients with A1C ≥5.6% 
were among subjects with DM (DM+ and DM+/AD+) 
compared to both DM-/AD- and AD. The percentage of 
prediabetics/diabetics, based on abnormal A1Cs, increase 
from 39% (DM-/AD-) to 88% (DM+), 50% (AD+), and 
100% (DM+/AD+; Figure 2F). Tobacco use (P<0.01, 
Figure 2G) was significantly higher among DM and AD 
groups compared to DM-/AD-.
Outcomes
Differences in NIHSS was assessed using ordinal logistic 
regression. Results are presented in the first three sections 
of Table 2. Regardless of adjusting for age, sex, and 
comorbidities, DM+/AD+ patients were significantly more 
likely to have had a moderate or severe stroke compared 
to the other three groups. Using parameter estimates 
from Model 3 (Table 2), DM+/AD+ patients were 10 times 
(i.e., 1/0.10=10) more likely to have had a moderate or 
severe stroke based on the admission NIHSS (Figure 3A). 
At discharge, DM+/AD+ patients were approximately 
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Table 2 Regression analysis for outcome measures of hemorrhagic stroke patients
Variable
Model 1 Model 2 Model 3
Odds ratio 
(SE)
95% CI P value
Odds ratio 
(SE)
95% CI P value
Odds ratio 
(SE)
95% CI P value
Admission NIHSS†
-DM/-AD (n=835) 0.11 (0.78) 0.02–0.59 0.008 0.12 (0.78) 0.02–0.66 0.012 0.10 (0.80) 0.02–0.55 0.006
DM+ (n=369) 0.12 (0.78) 0.02–0.67 0.013 0.13 (0.78) 0.02–0.72 0.017 0.11 (0.80) 0.02–0.59 0.009
AD+ (n=23) 0.13 (0.87) 0.02–0.87 0.033 0.12 (0.87) 0.02–0.80 0.026 0.09 (0.88) 0.01–0.63 0.013
DM/AD (n=11) 1.0 (ref) 1.0 (ref) 1.0 (ref)
Discharge NIHSS†
-DM/-AD (n=835) 0.21 (0.65) 0.05–0.86 0.028 0.25 (0.65) 0.06–1.03 0.055 0.22 (0.65) 0.05–0.92 0.036
DM+ (n=369) 0.21 (0.65) 0.05–0.89 0.032 0.24 (0.65) 0.06–1.00 0.050 0.22 (0.66) 0.05–0.91 0.036
AD+ (n=23) 0.42 (0.76) 0.08–2.18 0.366 0.38 (0.76) 0.07–1.97 0.297 0.32 (0.76) 0.06–1.70 0.211
DM/AD (n=11) 1.0 (ref) 1.0 (ref) 1.0 (ref)
Change NIHSS†
-DM/-AD (n=835) 0.46 (0.58) 0.13–1.62 0.270 0.41 (0.58) 0.11–1.46 0.195 0.37 (0.59) 0.10–1.35 0.151
DM+ (n=369) 0.49 (0.59) 0.14–1.77 0.335 0.46 (0.59) 0.13–1.66 0.282 0.44 (0.59) 0.12–1.57 0.243
AD+ (n=23) 0.32 (0.69) 0.07–1.47 0.166 0.36 (0.70) 0.08–1.64 0.219 0.34 (0.70) 0.07–1.55 0.187
DM/AD (n=11) 1.0 (ref) 1.0 (ref) 1.0 (ref)
Unfavorable discharge‡
-DM/-AD (n=1,459) 0.21 (0.58) 0.06–0.76 0.014 0.33 (0.59) 0.09–1.19 0.097 0.26 (0.59) 0.07–0.96 0.040
DM+ (n=567) 0.25 (0.58) 0.07–0.87 0.028 0.33 (0.59) 0.09–1.20 0.099 0.31 (0.59) 0.08–1.29 0.078
AD+ (n=29) 0.55 (0.69) 0.12–2.46 0.532 0.46 (0.70) 0.10–2.10 0.383 0.36 (0.71) 0.08–1.70 0.234
DM/AD (n=16) 1.0 (ref) 1.0 (ref) 1.0 (ref)
Average stay (log 
transformed)§
Mean (SE) Mean (SE) Mean (SE)
-DM/-AD (n=1,459) 1.63 (0.03) 0.489 1.61 (0.03) 0.177 1.95 (0.06) 0.748
DM+ (n=567) 1.71 (0.05) 0.684 1.74 (0.05) 0.381 1.92 (0.07) 0.657
AD+ (n=29) 1.28 (0.21) 0.123 1.47 (0.21) 0.138 1.82 (0.21) 0.515
DM/AD (n=16) 1.83 (0.28) REF 1.99 (0.28) REF 2.04 (0.27) REF
DM+, AD+ served as the reference group for analysis. Data are odds ratios and 95% CI or mean (SE). Both P values and confidence 
intervals were calculated using Dunnett’s multiple comparison procedure. Model 1: unadjusted; Model 2: adjusted for age and sex; Model 
3: adjusted for age, sex, type of hemorrhage, race, and all comorbidities (other than DM and AD). NIHSS was transformed into ordinal 
variables defined as: 0–5= mild, 6–13= moderate, and >13= severe stroke. The change (Admission-Discharge) in NIHSS was transformed 
into an ordinal variable based on whether the patient was: declining, staying the same, or improving. Discharge destination transformed 
into binary variable and classified as favorable or unfavorable. †Ordinal logistic regression. ‡Logistic regression. §Linear Regression. CI, 
confidence interval; DM, diabetes mellitus; AD, Alzheimer’s disease; NIHSS, National Institutes of Health Stroke Scale; SE, standard error.
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Figure 3 Hemorrhagic stroke outcomes among KApSR patients. NIHSS was transformed into ordinal variables defined as: 0–5= mild, 6–13= 
moderate, and >13= severe stroke for (A) admission and (B) discharge outcomes. (C) Inpatient outcomes defined as improving, same, or 
declining NIHSS (Admission-Discharge). (D) Discharge destination transformed into binary variable classified as favorable or unfavorable. 
Data are represented as percentage variables. P values were assessed by Chi-squared, 4×3, followed by followed 2×3. *P<0.05, **P<0.01 indicates 
significance from -DM/-AD. ^P<0.05 and ^^P<0.01 indicates significance from DM. #P<0.05 indicates significance from AD. AD, Alzheimer’s 
disease; DM, diabetes mellitus; KApSR, Kentucky Appalachian Stroke Registry; NIHSS, National Institute of Heath Stroke Scale.
A B
C D
4.5 times more likely to be in the moderate or severe 
NIHSS categories compared to DM-/AD- and DM+, 
which translated into DM+/AD+ subjects having a higher 
percentage of strokes classified as severe at discharge 
(Figure 3B). However, even though DM+/AD+ patients 
had significantly worse admission and discharge NIHSS, 
their change in NIHSS (admission–discharge) indicating 
in patient outcome was not significantly different from the 
other three groups (Figure 3C, Table 2).
The relationship between comorbidity condition and 
experiencing an unfavorable discharge was examined 
using logistic regression. The DM+/AD+ subjects had a 
significantly higher percentage of unfavorable discharge 
destinations compared to DM-/AD- and DM+ (Figure 3D). 
Interestingly, when adjusting for age and sex (model 2), 
discharge destination was not significantly different among 
groups. However, in the unadjusted (model 1) and adjusted 
for age, sex, and comorbidities (model 3; Table 2), the odds 
of DM+/AD+ having an unfavorable discharge destination 
was significant (P<0.05) from DM-/AD- and DM+. The 
average number of days in the hospital (Table 2, regardless 
of modeling) was not significantly different from the DM+/
AD+ group.
Several of the covariates included in Model 3 were 
significantly related to the outcomes. In particular, older 
individuals were more likely to have had a moderate to 
severe stroke based on their discharge NIHSS, they were 
less likely to remain stable or improve from admission to 
discharge, and were more likely to have an unfavorable 
outcome. Additionally, stroke type was a strong predictor 
of outcomes. Compared to those who experienced a SAH 
stroke, those who had an ICH stroke were more likely to 
have experienced a moderate to severe stroke based on both 
admission and discharge NIHSS, were less likely to remain 
stable or improve, and were more likely to experience an 
unfavorable discharge destination.
Discussion
Compared to ischemic stroke, hemorrhagic stroke leads to 
a higher mortality rate (22,23), increased need for palliative 
care (24), and higher hospitalization costs (25) associated 
with higher Medicare expenditures (26). This highlights the 
need to predict outcomes and manage comorbidities before 
hemorrhagic strokes occur. Studies have looked at the risk 
of AD and dementia after stroke (27,28), but few studies 
have looked at hemorrhagic stroke risk in patients with 
AD (29). Our study found DM+/AD+ patients had more 
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severe hemorrhagic strokes (higher NIHSS) at admission 
and discharge that contributed to a larger percentage with 
unfavorable discharge destinations. No differences between 
groups were observed for length of hospital stay and 
inpatient outcomes.
The presence of comorbidities is known to increase 
mortality following stroke (30,31). Specifically, high blood 
glucose, as occurs in diabetes, is associated with early 
mortality (32). An abnormal A1c may be an indicator that 
the patient is prediabetic or not managing their diabetes 
with their current regimen, possibly due to a lack of 
diagnosis, ability to treat, or patient compliance.
DM increases the risk of developing AD (33-36), and 
the metabolic changes associated with DM can initiate/
accelerate AD pathologies through oxidative stress, 
inflammation, and vascular injury (37). AD is associated 
with amyloid and tau pathologies that damage neurons or 
weaken the vasculature. Changes in cognition associated 
with AD may be associated with the weakening of the 
cerebrovasculature that can present years before damage is 
apparent. Higher percentage of prior strokes among the AD 
population may be due to amyloid deposition (38), which 
repeatedly weakens the vasculature. Diabetes treatment 
has been shown to lower amyloid load (39,40). However, 
the effects of controlling A1c values are controversial in 
dementia (39-42) due to adverse effects of hypoglycemias 
on the brain. DM+/AD+ subjects in KApSR have lower 
A1c’s, indicating controlled diabetes, but significantly 
worse NIHSS following hemorrhagic stroke. This suggests 
the importance of controlling diabetes, while preventing 
hypoglycemia, to prevent vascular injury and altered 
cognition. Patients with AD have higher relative risk and 
absolute rates of hemorrhagic stroke compared to non-AD 
controls (10,29,43-45). In our analysis, when controlling for 
age, the AD population had the worst outcomes.
Several  l imitations should be considered when 
interpreting these results, including disparities in: diet 
(46,47), physical activity (48), socio-economic status (49), 
race (50), and drug use (51-54), all inherent to the rural 
Appalachian population (55,56). We used the diagnosis of 
AD rather than the broader umbrella term dementia. While 
AD is just one type of dementia (57) it accounts for ~60–
70% of the cases (58). Diagnosis of AD and other dementias 
may be severely underreported or underdiagnosed, as occurs 
nationally (59-61), but may be heightened due to inherit 
health disparities in rural Appalachia. Additional cognitive 
and brain imaging diagnosis tools, such as computed 
tomography (CT), magnetic resonance imaging (MRI), or 
positron emission tomography (PET), were not available 
in this study. Any current medications for comorbidities, 
including diabetes, were also not available for our analysis. 
Comorbidities can also affect ischemic stroke, which can 
also lead to a secondary hemorrhagic stroke. As our analysis 
only included hemorrhagic strokes coded as primary 
diagnosis, the effect of diabetes and AD on a secondary 
hemorrhagic stroke was not analyzed and may be considered 
a limitation in our study. However, previous studies suggest 
alternate comorbidities may be associated with secondary 
hemorrhagic stroke following ischemic stroke. Arboix et al. 
found hemorrhagic lacunar stroke patients were more like 
to have hypertension, than diabetes (62) and patients with 
hemorrhagic stroke following cardioembolic stroke had a 
higher association with atrial fibrillation (63).
In conclusion, diabetes and AD should be considered 
as risk factors for an unfavorable outcome following 
hemorrhagic stroke. Diabetic screening and education 
for the AD population/caregivers is critical in addressing 
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Table S1 Predictors of missing NIHSS
Predictor Not missing NIHSS (n=1238) Missing NIHSS (n=833) Odds ratio (95% CI) P value
AD+/DM+ group
DM+/AD+ 11 (68.8%) 5 (31.2%) Ref 0.613
DM+ 369 (65.1%) 198 (34.9%) 0.96 (0.30–3.10)
AD+ 23 (79.3%) 6 (20.7%) 0.49 (0.11–2.21)
DM-/AD- 835 (57.2%) 624 (42.8%) 0.96 (0.30–3.07)
Age, mean (SD) 65.63 (15.21) 50.04 (15.61) 0.99 (0.98–0.99) <0.001
Sex 0.021
Male 646 (64.0%) 363 (36.0%) Ref
Female 592 (55.7%) 470 (44.3%) 1.27 (1.04–1.54)
Race 0.056
White 1,112 (59.6%) 754 (40.4%) Ref
Other 124 (61.7%) 77 (38.3%) 0.72 (0.52–1.01)
Stroke type <0.001
ICH 1,033 (71.3%) 415 (28.7%) Ref
SAH 205 (32.9%) 418 (67.1%) 4.38 (3.52–5.45)
Comorbidities
Hypertension 1,128 (62.2%) 685 (37.8%) 0.67 (0.49–0.90) 0.008
Atrial fibrillation 241 (68.1%) 113 (31.9%) 1.04 (0.79–1.38) 0.760
Coronary artery disease 316 (65.4%) 167 (34.6%) 1.14 (0.88–1.49) 0.326
Tobacco 471 (58.8%) 330 (41.2%) 0.78 (0.63–0.96) 0.019
Obesity 192 (62.5%) 115 (37.5%) 0.82 (0.62–1.09) 0.167
Dyslipidemia 566 (69.2%) 252 (30.8%) 0.64 (0.52–0.80) <0.001
Carotid stenosis 65 (82.3%) 14 (17.7%) 0.41 (0.22–0.76) 0.005
Prior stroke/transient ischemic attack 259 (70.0%) 111 (30.0%) 0.91 (0.69–1.18) 0.468
Acute myocardial infarction 74 (61.1%) 47 (38.8%) 0.86 (0.57–1.31) 0.483
History myocardial infarction 71 (59.2%) 49 (40.8%) 1.51 (0.98–2.33) 0.065
Data are n (percent) and odds ratios with a 95% CI. Both P values and confidence intervals were calculated using Dunnett’s multiple 
comparison procedure. AD, Alzheimer’s disease; CI, confidence interval; DM, diabetes mellitus; ICH, intracerebral hemorrhage; SD, 
standard deviation; SAH, subarachnoid hemorrhage.
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